CA2612644A1 - Modulation de la signalisation de la sphingosine kinase - Google Patents

Modulation de la signalisation de la sphingosine kinase Download PDF

Info

Publication number
CA2612644A1
CA2612644A1 CA002612644A CA2612644A CA2612644A1 CA 2612644 A1 CA2612644 A1 CA 2612644A1 CA 002612644 A CA002612644 A CA 002612644A CA 2612644 A CA2612644 A CA 2612644A CA 2612644 A1 CA2612644 A1 CA 2612644A1
Authority
CA
Canada
Prior art keywords
sphingosine kinase
eef1a
activity
interaction
eef1a1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002612644A
Other languages
English (en)
Inventor
Stuart M. Pitson
Tamara Leclercq
Mathew Alexander Vadas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medvet Science Pty Ltd
Original Assignee
Medvet Science Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005903257A external-priority patent/AU2005903257A0/en
Application filed by Medvet Science Pty Ltd filed Critical Medvet Science Pty Ltd
Publication of CA2612644A1 publication Critical patent/CA2612644A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
    • C12Y207/01—Phosphotransferases with an alcohol group as acceptor (2.7.1)
    • C12Y207/01091—Sphinganine kinase (2.7.1.91)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002612644A 2005-06-21 2006-06-21 Modulation de la signalisation de la sphingosine kinase Abandoned CA2612644A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2005903257A AU2005903257A0 (en) 2005-06-21 A method of modulating enzyme activity and agents for use therein
AU2005903257 2005-06-21
PCT/AU2006/000866 WO2006135968A1 (fr) 2005-06-21 2006-06-21 Modulation de la signalisation de la sphingosine kinase

Publications (1)

Publication Number Publication Date
CA2612644A1 true CA2612644A1 (fr) 2006-12-28

Family

ID=37570027

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002612644A Abandoned CA2612644A1 (fr) 2005-06-21 2006-06-21 Modulation de la signalisation de la sphingosine kinase

Country Status (4)

Country Link
EP (1) EP1910524A4 (fr)
JP (1) JP2008546721A (fr)
CA (1) CA2612644A1 (fr)
WO (1) WO2006135968A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8324237B2 (en) 2005-05-20 2012-12-04 Smith Charles D Methods for the treatment and prevention of inflammatory diseases
JP2008546393A (ja) * 2005-06-21 2008-12-25 メドベット サイエンス ピーティーワイ． リミティッド スフィンゴシンキナーゼのシグナル伝達の調節
EP2166094A1 (fr) 2008-09-23 2010-03-24 Ecole Normale Superieure De Lyon Procédés pour le prolongement des avantages sanitaires déclenchés par une restriction alimentaire utilisant un inhibiteur de la sphingosine kinase

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPQ744700A0 (en) * 2000-05-11 2000-06-01 Medvet Science Pty. Ltd. A method of treatment and agents useful for same

Also Published As

Publication number Publication date
EP1910524A4 (fr) 2009-04-01
EP1910524A1 (fr) 2008-04-16
WO2006135968A1 (fr) 2006-12-28
JP2008546721A (ja) 2008-12-25

Similar Documents

Publication Publication Date Title
AU2001256001B2 (en) Sphingosine kinase and uses thereof
AU8965898A (en) A method of modulating cellular activity
CA2612644A1 (fr) Modulation de la signalisation de la sphingosine kinase
NZ529983A (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
AU2009201639A1 (en) A method of modulating cellular activity
CA2612773A1 (fr) Modulation de la signalisation de la sphingosine kinase
CA2595469A1 (fr) Procede de traitement d'un dommage cellulaire
AU2006261583A1 (en) Modulation of sphingosine kinase signalling
AU2005253643B2 (en) Methods of modulating cellular activity involving sphingosine kinase and agents for same, and sphingosine kinase variants
AU2006261584A1 (en) Modulation of sphingosine kinase signalling
CA2569687A1 (fr) Procede de modulation de l'activite cellulaire faisant intervenir une sphingosine kinase, agents utilises a cet effet et variantes de sphingosine kinase
NZ523343A (en) Novel therapeutic molecular variants and uses thereof
AU2006207818A1 (en) A method of treating cellular damage
CA2612640A1 (fr) Modulation de la signalisation de l'egfr par modulation de la signalisation de sphingosine kinase
AU2002304973B2 (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
US20060111286A1 (en) Method of modulating endothelial cell activity
Xia 2. An isolated polynucleotide according to claim 1, the polynucleotide comprising a sequence at least 95% identical to SEQ ID NO: 1. 3. An isolated polynucleotide sequence that hybridizes to the nucleotide sequence of claim 2 stringency conditions of about 65 C C. and about 50% v/v formamide and about 0.15 M salt. 4. An isolated polynucleotide according to claim 1, the polynucleotide encoding a polypeptide having the sequence of SEQ ID NO: 2. 5. An isolated polynucleotide according to claim 1, the polynucleotide comprising the sequence of SEQ ID NO: 1. 6. An expression system comprising a polynucleotide according to claim 1.
EP1558736A1 (fr) Procede visant a moduler l'activite d'une cellule epitheliale a l'aide de la modulation des niveaux fonctionnels de sphingosine kinase
AU2006261582A1 (en) Modulation of EGFR signalling by modulation of sphingosine kinase signalling
WO2004100978A1 (fr) Procede de modulation de la transmigration cellulaire et agents utilises a cet effet
AU2004238086A1 (en) A method of modulating cellular transmigration and agents for use therein
AU2003258356A1 (en) A method of modulating endothelial cell activity
AU2003269592A1 (en) A method of modulating epithelial cell activity by modulating the functional levels of sphingosine kinase
AU2002304973A1 (en) Sphingosine kinase interacts with TRAF2 and modulates tumor necrosis factor-induced cellular activity
ZA200300214B (en) Novel therapeutic molecular variants and uses thereof.

Legal Events

Date Code Title Description
FZDE Dead